Alembic Ltd Share Price – NSE /  BSE

Realty, Small Cap

Alembic announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the final dividend of Rs 2.4 per equity Share (i.e. 120%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Alembic declined 5.13% to Rs 68.45 crore in the quarter ended March 2025 as against Rs 72.15 crore during the previous quarter ended March 2024. Sales rose 22.90% to Rs 60.27 crore in the quarter ended March 2025 as against Rs 49.04 crore during the previous quarter ended March 2024.

For the full year,net profit rose 15.66% to Rs 310.68 crore in the year ended March 2025 as against Rs 268.62 crore during the previous year ended March 2024. Sales rose 40.89% to Rs 221.89 crore in the year ended March 2025 as against Rs 157.49 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Alembic will hold a meeting of the Board of Directors of the Company on 13 May 2025.

Powered by Capital Market - Live News

Profit before tax (PBT) was at Rs 27.39 crore in Q3 FY25, up 151.75% as against Rs 10.88 crore reported in the same period a year ago.

Total expense jumped 13.79% year on year to Rs 34.90 crore during the quarter. Employee benefit expense stood at Rs 6.56 crore (up 17.56% YoY), while cost of materials consumed was at Rs 1.81 crore (up 14.56% YoY) during the period under review.

The company’s revenue from the active pharmaceutical ingredients business was at Rs 6.25 crore (down 3.55% YoY), while the real estate business came in at Rs 51.67 crore (up 57.29% YoY) during the period under review.

On a 9-month basis, the net profit surged 68.8% to Rs 120.83 crore on a 49.04% rise in revenue from operations to Rs 161.62 crore in 9M FY25 over 9M FY24.

Alembic is dealing in the Active Pharmaceutical Ingredient (API) Business and Real Estate Business.

Shares of Alembic fell 1.69% to Rs 110.85 on the BSE.

Powered by Capital Market - Live News